Association between ethnicity and degree of improvement in cardiac function following initiation of sacubitril/valsartan. Issue 1 (January 2022)

• Record Type: Journal Article
• Authors: Holm, Niels; Bromage, Daniel I.; Cannata, Antonio; DeCourcey, Julia; Bhatti, Prashan; Huang, Marilou; McDonagh, Theresa A.
• Is Part Of: Journal of cardiovascular medicine. Volume 23:Issue 1(2022)
• Publication Date: 2022-01
• Subjects: ejection fraction -- ethnicity -- heart failure -- heart failure and reduced ejection fraction -- sacubitril/valsartan; Cardiology -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; Cardiology -- Periodicals; Cardiovascular Diseases -- Periodicals; 616.1005
• DOI: 10.2459/JCM.0000000000001268
• Languages: English
• ISSNs: 1558-2027

Abstract

Abstract : Aims: The aim of this study was to determine the degree of short-term improvement in left ventricular ejection fraction (LVEF), haemodynamics, NT-proBNP and quality of life following initiation of sacubitril/valsartan in black patients when compared with white patients. Methods: This was a retrospective, observational, single-centre, hypothesis-generating study of patients with symptomatic heart failure and reduced ejection fraction (HFrEF) treated with guideline recommended therapy, who were transitioned from an ACE inhibitor (ACE-I) or angiotensin receptor blocker (ARB) to sacubitril/valsartan. Results: Our analysis included 83 patients (mean age 57 years) with echocardiography performed before and after transition from ACE-I/ARB to sacubitril/valsartan, after excluding patients with concomitant Cardiac resynchronization therapy implantation. Overall, sacubitril/valsartan was associated with LVEF improvement from 28.8% ± 0.7 to 32.0% ± 1.1% ( P = 0.0002), but no reverse remodelling was observed. The association with LVEF improvement was only observed in white patients ( n = 46, P = 0.0006), but not in black patients ( n = 37, P = 0.1728), and appeared to be associated with reduced blood pressure (baseline vs. 2-week blood pressure 116.5 ± 13.9 vs. 109.4 ± 14.3 mmHg, respectively, in white patients, P = 0.0449). Fifteen patients (18.1%) became ineligible for primary prevention Implantable cardioverter defibrillator implantation. Conclusion: Sacubitril/valsartan was associated with improved LVEF, NT-proBNP concentrations and quality of life in patients with symptomatic HFrEF on guideline recommended therapy. However, in our cohort, improvement of LVEF and quality of life might be attenuated in black patients, which warrants further investigation.